Literature DB >> 3028459

Binding of urokinase to specific receptor sites on human breast cancer membranes.

G K Needham, G V Sherbet, J R Farndon, A L Harris.   

Abstract

The high molecular weight form of the plasminogen activator urokinase (54 kD) binds to specific receptor sites on the cell membrane of breast carcinomas by its inactive "A" chain. The binding is of high affinity (range of dissociation constants: 5.6 X 10(-11) to 4 X 10(-10) mol l-1 and there were between 20 to 250 fmol of binding sites per milligram of membrane protein) and equilibrium is reached in 60 min. No competition for binding sites was observed with epidermal growth factor, tissue plasminogen activator or the low molecular weight form of urokinase (33 kD). Cross-linking experiments suggest that the receptor is a monomeric unit of molecular weight of 50 kD. This binding site provides a mechanism for the incorporation of urokinase into the cell membrane.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3028459      PMCID: PMC2001562          DOI: 10.1038/bjc.1987.3

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts.

Authors:  M Del Rosso; G Dini; G Fibbi
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

2.  Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.

Authors:  M P Stoppelli; A Corti; A Soffientini; G Cassani; F Blasi; R K Assoian
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

Review 3.  Plasminogen activators, tissue degradation, and cancer.

Authors:  K Danø; P A Andreasen; J Grøndahl-Hansen; P Kristensen; L S Nielsen; L Skriver
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

Review 4.  The role of proteinases in cellular invasiveness.

Authors:  D E Mullins; S T Rohrlich
Journal:  Biochim Biophys Acta       Date:  1983-12-29

5.  Localization of plasminogen activator(s) in primary and secondary rat adenocarcinoma cells.

Authors:  R Ng; A Wong; J A Kellen
Journal:  Clin Exp Metastasis       Date:  1985 Jan-Mar       Impact factor: 5.150

6.  Tissue plasminogen activator: chemical and physiological aspects.

Authors:  F Bachmann; I E Kruithof
Journal:  Semin Thromb Hemost       Date:  1984-01       Impact factor: 4.180

7.  Receptors for epidermal growth factor in the rat uterus.

Authors:  V R Mukku; G M Stancel
Journal:  Endocrinology       Date:  1985-07       Impact factor: 4.736

8.  Evidence that a variety of cultured cells secrete protease nexin and produce a distinct cytoplasmic serine protease-binding factor.

Authors:  D L Eaton; J B Baker
Journal:  J Cell Physiol       Date:  1983-11       Impact factor: 6.384

9.  Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells.

Authors:  T J Ryan; J I Seeger; S A Kumar; H W Dickerman
Journal:  J Biol Chem       Date:  1984-12-10       Impact factor: 5.157

10.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

Authors:  J D Vassalli; D Baccino; D Belin
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

View more
  6 in total

1.  The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells.

Authors:  S M Abidi; E W Howard; J J Dmytryk; J T Pento
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

2.  beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.

Authors:  S Hapke; M Gawaz; K Dehne; J Köhler; J F Marshall; H Graeff; M Schmitt; U Reuning; E Lengyel
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.

Authors:  Kyung Hee Lee; Myung Soo Hyun; Jae-Ryong Kim
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

4.  Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.

Authors:  E Rønne; G Høyer-Hansen; N Brünner; H Pedersen; F Rank; C K Osborne; G M Clark; K Danø; J Grøndahl-Hansen
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

5.  Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.

Authors:  R Picone; E L Kajtaniak; L S Nielsen; N Behrendt; M R Mastronicola; M V Cubellis; M P Stoppelli; S Pedersen; K Danø; F Blasi
Journal:  J Cell Biol       Date:  1989-02       Impact factor: 10.539

6.  Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.

Authors:  A S Levenson; H C Kwaan; K M Svoboda; I M Weiss; S Sakurai; V C Jordan
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.